Brief: Kymera Therapeutics Announces Third Quarter 2024 Financial Results

Kymera Therapeutics

31/10/2024 11:52

Oct 31 (Reuters) - Kymera Therapeutics Inc  KYMR.O :
    * KYMERA THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 FINANCIAL
RESULTS AND PROVIDES A BUSINESS UPDATE
    * KYMERA THERAPEUTICS: TO ONLY ADVANCE KT-333 (STAT3) AND
KT-253
(MDM2) BEYOND PHASE 1 WITH A PARTNER
    * KYMERA THERAPEUTICS INC: TO SHIFT FOCUS AND RESOURCES FROM
ONCOLOGY TO ITS EXPANDING IMMUNOLOGY PIPELINE
    * KYMERA THERAPEUTICS INC: KT-295, NEW TYK2 DEGRADER,
SELECTED AS
DEVELOPMENT CANDIDATE TO ADVANCE INTO PHASE 1 CLINICAL TRIAL IN
H1 2025

Source text:  ID:nGNX62fmfQ 
Further company coverage:  KYMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))